Haviland Kate 4

What Happened
Kate Haviland, a director of Bicara Therapeutics, was granted a derivative award covering 19,475 shares on 2026-06-09. The reported acquisition price is $0.00 (derivative grant), so there was no cash paid at the time of grant. This filing reports an award (transaction code A), not a sale or open-market purchase.

Key Details

• Transaction date: 2026-06-09; filing date: 2026-06-10 (timely).
• Grant details: 19,475 shares @ $0.00 (derivative award).
• Shares owned after transaction: not disclosed in the provided filing data.
• Vesting footnote: shares underlying the stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of stockholders, subject to continued service.
• Transaction type: Award/Grant (code A); this is a derivative (stock option-like award) and was not exercised or sold.

Context
This is a compensation-related award to a director and vests based on continued service and timing of the next annual meeting. Because it is a vesting derivative grant rather than an open-market purchase or sale, it does not reflect an immediate change in market exposure (no shares were sold or exercised at grant).